Learning to adapt to constant numbness and tingling in her hands has given columnist Cazandra Campos-MacDonald new insight into her sons.

Columnist G Shellye Horowitz shares the many miracles she's experienced in her life despite living with the bleeding disorder ...

CHMP has advised that Alhemo be approved for people with severe hemophilia A and moderate or severe hemophilia B without inhibitors.

Columnist Alliah Czarielle's husband may live with chronic illnesses, but she still has high standards in their relationship.

Columnist Joe MacDonald shares his practical advice for how to help a child define their identity beyond their hemophilia diagnosis.

Columnist G Shellye Horowitz shares tips you can use to support a loved one who may be feeling anxiety due to concerns about hemophilia.

Pfizer Inc. (NYSE:PFE) intends to present the data to regulatory bodies in order to start the regulatory filing process for HYMPAVZI in hemophilia patients with inhibitors. The medication has ...

A retired pharmacist may have been cured from life threatening hemophilia B during "innovative" gene therapy treatment at Vanderbilt.

Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third-quarter 2025 dividend of $0.43 per share. Alongside these ...

Pfizer (PFE) stock in focus as its hemophilia drug Hympavzi succeeds in a Phase 3 trial. Read more here.

NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents ...